Article: BB Medtech AG Makes $12 Million Investment In Israeli Biotech Company.

BB Medtech a part of Swiss Bellevue asset management group, which manages over $2 billion, made a $12 million investment in Combact Diagnostic Systems. The Israeli biotech company is developing a process to automatically detect bacteria in urine. Instead of doctors and patients having to wait days for urine tests to be returned from diagnostic laboratories, this process will enable doctors to receive almost on the spot results. This is Combact third round of financing. In this round the company has raised $14.5 million and intends to raise a total of $20 million. In Combact's pervious private placements both ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!